SpringerLink
Log in

Urinary citrate as a marker of renal function in patients with autosomal dominant polycystic kidney disease

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is frequent to find low urinary citrate levels. Recently, it has been suggested that urinary citrate could be a marker of covert metabolic acidosis in chronic kidney disease.

Objective

Our aim was to analyze relationship between urinary citrate levels, renal function, and serum bicarbonate in ADPKD patients.

Methods

We determined citrate in 24-h collected urine from ADPKD patients and correlated with glomerular filtration rate (CKD-EPI equation) and serum bicarbonate concentration.

Results

We included 120 patients, 60% men, eGFR was 71 ± 32 mL/min/1.73 m2. Urinary citrate/creatinine ratio was 195 ± 152 mg/gCr (range 1.2–689) with levels significantly higher in females. Urinary citrate lower than 300 mg/gCr was present in 75% of patients and when considering chronic kidney stages (CKD), we observed reduced levels in 48.8% in CKD1 stage, in 79.4% in CKD2 stage, in 96.2% in CKD3 stage, and in 94.7% of patients in CKD4 stage. Urinary citrate was correlated with serum creatinine (r = − 0.61, p < 0.001) and eGFR (r = 0.55, p < 0.001) in both gender. We did not find any correlation with serum bicarbonate. Using a general linear modeling analysis, we found as predictors of urinary citrate/creatinine ratio to glomerular filtration rate, gender, and age. Lower levels of urinary citrate were accompanied by a decline in urinary osmolality and in renal excretion of calcium and uric acid. In a subgroup of patients, we measured total kidney volume and we found an inverse correlation with urinary citrate levels that disappeared when it was corrected with glomerular filtration rate.

Conclusions

Urinary citrate is very frequently reduced in ADPKD patients being present from very early CKD stages. Their levels in urine are inversely correlated with glomerular filtration rate and it is not related with serum bicarbonate concentration. We think that it would be interesting to study urinary citrate as a marker of chronic kidney disease in ADPKD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Hamm LL (1990) Renal handling of citrate. Kidney Int 38:728–735

    Article  CAS  Google Scholar 

  2. Baruch SB, Burich RL, Eun CK, King VF (1975) Renal metabolism of citrate. Med Clin North Am 59:569–582

    Article  CAS  Google Scholar 

  3. Unwin RJ, Capasso G, Shirley DG (2004) An overview of divalent cation and citrate handling by the kidney. Nephrol Physiol 98:15–20

    Article  Google Scholar 

  4. Hering-Smith KS, Mao W, Schiro FR, Coleman-Barnett J, Pajor AM, Hamm LL (2014) Localization of the calcium regulated citrate transport process in proximal tubule cells. Urolithiasis 42(3):209–2019

    Article  CAS  Google Scholar 

  5. Nishiura JL, Neves RFCA, Eloi SRM, Cintra SMLF, Ajzen SA, Heilberg IP (2009) Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 4:838–844

    Article  CAS  Google Scholar 

  6. Torres VE, Wilson DM, Hattery RR, Segura JW (1993) Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 22(4):513–519

    Article  CAS  Google Scholar 

  7. Levine E, Grantham JJ (1992) Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease: clinical and CT study in 84 patients. AJR Am J Roentgenol 159:77–81

    Article  CAS  Google Scholar 

  8. Torres VE, Erickson SB, Smith LH, Wilson DM, Hattery RR, Segura JW (1988) The association of nephrolithiasis and autosomal dominant polycystic kidney disease. Am J Kidney Dis 11(4):318–325

    Article  CAS  Google Scholar 

  9. Ogborn MR, Sareen S, Prychitko J, Buist R, Peeling J (1997) Altered organic anion and osmolyte content and excretion in rat polycystic kidney disease: an NMR study. Am J Physiol 272:F63–F69

    CAS  Google Scholar 

  10. Torres VE, Keith DS, Offord KP, Kon SP, Wilson DM (1994) Renal ammonia in autosomal dominant polycystic kidney disease. Kidney Int 45:1745–1753

    Article  CAS  Google Scholar 

  11. Goraya N, Simoni J, Sager LN, Madias NE, Wesson DE (2019) Urine citrate excretion as a marker of acid retention in patients with chronic kidney disease without overt metabolic acidosis. Kidney Int 95(5):1190–1196

    Article  CAS  Google Scholar 

  12. Goraya N, Simoni J, Sager LN, Mamun A, Madias NE, Wesson DE (2019) Urine citrate excretion identifies changes in acid retention as eGFR declines in patients with chronic kidney disease. Am J Physiol Renal Physiol 317(2):F502–F511

    Article  CAS  Google Scholar 

  13. Goraya N, Simoni J, Sager LN, Pruszynski J, Wesson DE (2018) Acid retention in chronic kidney disease is inversely related to GFR. Am J Physiol Renal Physiol 314(5):F985–F991

    Article  CAS  Google Scholar 

  14. Prot-Bertoye C, Vallet M, Houillier P (2019) Urinary citrate: helpful to predict acid retention in CKD patients? Kidney Int 95(5):1020–1022

    Article  Google Scholar 

  15. Borrego Utiel FJ, Merino GE, Herrera I, Moriana C, Camacho V, Ocaña E, García Cortés MJ (2020) Low urinary citrate levels are not specific of autosomal polycystic kidney disease (ADPKD) and are present when renal function is impaired in all nephropaties. Nephrol Dial Transpl. https://doi.org/10.1093/ndt/gfaa142.P0234

    Article  Google Scholar 

  16. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, SanMillan JL, Gibson R, Breuning M, Peters D, Ravine D (2009) Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 20:205–212

    Article  CAS  Google Scholar 

  17. Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC, Conference Participants (2015) Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 88(1):17–27

  18. Moellering H, Gruber W (1966) Determination of citrate with citrate lyase. Anal Biochem 17(3):369–376

    Article  CAS  Google Scholar 

  19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612

  20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X (PMID: 18064739)

  21. Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ et al (2015) Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26(1):160–172

    Article  CAS  Google Scholar 

  22. Perinpam M, Ware EB, Smith JA, Turner ST, Kardia SLR, Lieske JC (2017) Association of urinary citrate excretion, pH, and net gastrointestinal alkali absorption with diet, diuretic use, and blood glucose concentration. Physiol Rep. https://doi.org/10.14814/phy2.13411

    Article  PubMed  PubMed Central  Google Scholar 

  23. Gershman B, Sheth S, Dretler SP et al (2012) Relationship between glomerular filtration rate and 24-hour urine composition in patients with nephrolithiasis. Urology 80(1):38–42

    Article  Google Scholar 

  24. Jhagroo RA, Wertheim ML, Penniston KL (2015) Alkali replacement raises urinary citrate excretion in patients with topiramate-induced hypocitraturia. Br J Clin Pharmacol 81:131–136

    Article  Google Scholar 

  25. Shea MK, Dawson-Hugues B (2018) Association of urinary citrate with acid-base status, bone resorption, and calcium excretio in older men and women. J Clin Endocrinol Metab 103:452–459

    Article  Google Scholar 

  26. Grampsas SA, Chandhoke PS, Fan J et al (2000) Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 36:53–57

    Article  CAS  Google Scholar 

  27. Gianella FG, Prado VE, Poindexter JR, Adams-Huet B, Li X, Miller RT, Sakhaee K, Maalouf NM, Moe OW (2021) Spot urinary citrate-to-creatinine ratio is a marker for acid-base status in chronic kidney disease. Kidney Int 99(1):208–217

    Article  CAS  Google Scholar 

  28. Tanner GA (1998) Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 9:1242–1248

    Article  CAS  Google Scholar 

  29. Navaneethan SD, Shao J, Buysse J, Bushinsky DA (2019) Effects of treatment of metabolic acidosis in CKD: a systematic review and meta-analysis. Clin J Am Soc Nephrol 14(7):1011–1020

    Article  CAS  Google Scholar 

  30. Goraya N, Wesson DE (2019) Clinical evidence that treatment of metabolic acidosis slows the progression of chronic kidney disease. Curr Opin Nephrol Hypertens 28(3):267–277

    Article  CAS  Google Scholar 

  31. Trinchieri A, Mandressi A, Luongo P, Rovera F, Longo G (1992) Urinary excretion of citrate, glycosaminoglycans, magnesium and zinc in relation to age and sex in normal subjects and in patients who form calcium stones. Scand J Urol Nephrol 26(4):379–386

    Article  CAS  Google Scholar 

  32. Hering-Smith KS, Schiro FR, Pajor AM, Hamm LL (2011) Calcium sensitivity of dicarboxylate transport in cultured proximal tubule cells. Am J Physiol Renal Physiol 300(2):F425–F432

    Article  CAS  Google Scholar 

  33. Walker WR, Zhang Sh, Coleman-Barnett Joycelynn A, Hamm LL, Hering-Smith KS (2018) Calcium receptor signaling and citrate transport. Urolithiasis 46(5):409–418

    Article  CAS  Google Scholar 

  34. Gafni RI, Langman CB, Guthrie LC, Brillante BA, James R, Yovetich NA, Boyce AM, Collins MT (2018) Hypocitraturia is an untoward side effect of synthetic human parathyroid hormone (hPTH) 1–34 therapy in hipoparathyroidism that may increase renal morbidity. J Bone Miner Res 33(10):1741–1747

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unidad de Gestión Clínica (UGC) de Nefrología, Hospital Universitario de Jaén, Avda Ejército Español 10, 23007, Jaén, Spain

    Francisco José Borrego Utiel, Enoc Merino García & Clara Moriana Domínguez

  2. UGC de Análisis Clínicos, Hospital Universitario de Jaén, Jaén, Spain

    Isidoro Herrera Contreras, Maria Victoria Camacho Reina & Esther Ocaña Pérez

Authors
  1. Francisco José Borrego Utiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isidoro Herrera Contreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Enoc Merino García
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Victoria Camacho Reina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Clara Moriana Domínguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Esther Ocaña Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Research idea and study design: FJBU; data acquisition: FJBU, IHC, MVCR, EMG, and CMD; data analysis/interpretation: FJBU, IHC, and EOP; statistical analysis: FJBU. Each author contributed important intellectual content during manuscript drafting or revision. All authors approved the final version of the manuscript.

Corresponding author

Correspondence to Francisco José Borrego Utiel.

Ethics declarations

Conflict of interest

Authors have not conflict of interest to declare. We have not received any financial support for this research. We declare that the results presented in this paper have not been published previously in whole or part, except in abstract format.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Borrego Utiel, F.J., Herrera Contreras, I., Merino García, E. et al. Urinary citrate as a marker of renal function in patients with autosomal dominant polycystic kidney disease. Int Urol Nephrol 54, 873–881 (2022). https://doi.org/10.1007/s11255-021-02953-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-021-02953-0

Keywords

Search

Navigation